Revenue of LEQEMBI (Preliminary Basis)
Filed with TSE · · 1 page · English
Watch Eisai's latest callEisai (Tokyo:4523) Q1 2027 Earnings Call · Replay · Aug 3Read the transcript of Eisai (Tokyo:4523) Q1 2027 Earnings CallEarlier from Eisai
- Notification Regarding Receipt of Dividend from a Consolidated Subsidiary
- U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
- Leqembi® Pen subcutaneous formulation approved in Japan
- LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease
- Eisai and Osaka Prefecture Enter into Collaboration to Promote Awareness of Dementia and Mild Cognitive Impairment (MCI)
Follow Eisai into a list and get an email when it puts out news.
Follow Eisai